Biogen and Ionis report positive topline clinical data on investigational Alzheimer’s disease treatment at AAIC

– Phase 1b study of BIIB080/IONIS-MAPT Rx met primary objective of safety and tolerability – Study demonstrated durable, robust, time and dose dependent lowering of tau protein in cerebrospinal fluid CAMBRIDGE, Mass. and CARLSBAD, Calif. , July 26, 2021 /PRNewswire/ —  Biogen Inc.